Nancy M. Schlichting
Known title: DirectorCIK: 0001376358
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Baxter International publishes inaugural Connected Hospital Report. Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.
Transaction History
| EHC | ▲ Buy | Grant | 40 | $0 | 7/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 1,634 | $0 | 5/7/2026 | View on chart |
| BAX | ▲ Buy | Grant | 12,836 | $0 | 5/5/2026 | View on chart |
| EHC | ▲ Buy | Grant | 39 | $0 | 4/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 40 | $0 | 1/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 33 | $0 | 10/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 34 | $0 | 7/15/2025 | View on chart |
| BAX | ▲ Buy | Grant | 7,183 | $0 | 5/6/2025 | View on chart |
| EHC | ▲ Buy | Grant | 1,424 | $0 | 5/1/2025 | View on chart |
| EHC | ▲ Buy | Grant | 33 | $0 | 4/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 36 | $0 | 1/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 35 | $0 | 10/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 35 | $0 | 7/15/2024 | View on chart |
| BAX | ▲ Buy | Grant | 5,952 | $0 | 5/7/2024 | View on chart |
| EHC | ▲ Buy | Grant | 1,978 | $0 | 5/2/2024 | View on chart |
| EHC | ▲ Buy | Grant | 33 | $0 | 4/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 37 | $0 | 1/16/2024 | View on chart |
| EHC | ▲ Buy | Grant | 42 | $0 | 10/16/2023 | View on chart |
| EHC | ▲ Buy | Grant | 39 | $0 | 7/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 2,385 | $0 | 5/4/2023 | View on chart |
| BAX | ▲ Buy | Grant | 4,573 | $0 | 5/2/2023 | View on chart |
| EHC | ▲ Buy | Grant | 37 | $0 | 4/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 37 | $0 | 1/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 46 | $0 | 10/17/2022 | View on chart |
| EHC | ▲ Buy | Grant | 85 | $0 | 7/20/2022 | View on chart |
| EHC | ▲ Buy | Grant | 2,226 | $0 | 5/5/2022 | View on chart |
| BAX | ▲ Buy | Grant | 2,706 | $0 | 5/3/2022 | View on chart |
| EHC | ▲ Buy | Grant | 40 | $0 | 4/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 46 | $0 | 1/18/2022 | View on chart |
| BAX | ▲ Buy | Grant | 743 | — | 12/13/2021 | View on chart |
| EHC | ▲ Buy | Grant | 42 | $0 | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date
Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.